<DOC>
	<DOC>NCT01152385</DOC>
	<brief_summary>The purpose of this study is to compare the effect on glucose control of 3 different AZD1656 dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as evaluated by the change in HbA1c from baseline to the end of treatment at 4 months.</brief_summary>
	<brief_title>Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>women of nonchildbearing potential. Provision of informed consent prior to any study specific procedures Naïve T2DM patients with HbA1c ≥ 7.5% but ≤ 10% or T2DM Patients treated with one or two oral antihyperglycaemic agent(s) with HbA1c ≥ 7.5% but ≤ 9.5% at enrolment visit (Visit1) Clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, hepatic disease and haematological disease. The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history. Participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 2</keyword>
	<keyword>AZD1656</keyword>
	<keyword>efficacy</keyword>
	<keyword>dose regimen</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>